Kevin O'Rourke M.D.

Kevin O'Rourke MD, PhD is an established professional in the life sciences sector, currently serving as the Director of Investments and Business Development at Roivant Sciences since May 2021, after holding positions as Senior Associate and Associate in the same domain. Notable accomplishments include the formation of Telavant and the in-licensing of RVT-3101 for patients with inflammatory bowel disease, as well as the establishment of Hemavant and the in-licensing of RVT-2001, currently involved in a Phase 2 trial for low-risk MDS. Previous experience includes strategic analysis roles at Regeneron and a fellowship at Flagship Pioneering. Kevin O'Rourke has been recognized as part of Forbes' 30 Under 30 in Healthcare and has a substantial academic background with an MD and a PhD in Cancer Biology and Genetics from Cornell University, in addition to a BA in Molecular Biology and Biochemistry from Middlebury College.